• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

    73.15 +0.54 (+0.74%)
    Delayed Quote Updated: 10:37 AM EDT, Oct 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ANI Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
    From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
    Via Business Wire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
    Via Investor Brand Network
    News headline image
    ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
    From ANI Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.